UBS Reiterates Buy Rating on Abbott Laboratories (ABT)

Market Context

Abbott Laboratories operates in the Healthcare sector. The stock currently trades at $107.32 with a market capitalization of $202.5B. The stock has declined 17.5% over the past 52 weeks.

Analyst coverage from UBS provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Abbott Laboratories.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Abbott Laboratories

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 28, 2026	UBS	Buy	N/A
Jul 17, 2026	TD Cowen	Buy	N/A
Jul 17, 2026	RBC Capital	Outperform	N/A
Jul 17, 2026	Wells Fargo	Overweight	N/A
Jul 17, 2026	Evercore ISI Group	Outperform	N/A

Related Tools: Analyst Ratings Dashboard | View ABT Stock Page